GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has hit the mark in two phase 3 trials and will be filed for approval as a potential first-in-class treatment for the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results